Opko Health (OPK -7.42%), a diversified healthcare company operating in diagnostics and pharmaceuticals, released its second quarter 2025 results on July 31, 2025. The company reported a significant revenue miss, with total GAAP revenue at $156.8 million, compared to analyst expectations of $165.7 million for Q2 2025. Its net loss per share on a GAAP basis reached $0.19, wider than estimates for a $0.11 loss and sharply higher than the prior-year figure in Q2 2025. Results were affected by lower diagnostics ...

The next-generation diagnostics specialist had a beat-and-raise second quarter.Friday's stock market was generally a gloomy place, but apparently someone forgot to tell Fulgent Genetics (FLGT 7.80%). The company's shares were soaring in late-session action, with a very healthy rise of more than 8%. At that point, the bellwether S&P 500 index was mired in a funk with a nearly 2% decline. Fulgent's latest earnings release was a major reason for this dichotomy.A surprise on the bottom lineThat morning, before ...

OPKO Health (OPK) Q2 2025 Earnings Call July 31, 2025 04:30 PM ET Speaker0Good day, and welcome to the OpCo Health Second Quarter twenty twenty five Financial Results Conference Call. All participants will be in a listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Yvonne Briggs. Please go ahead.Speaker1Thank you, operator, and good afternoon. This is Yvonne Briggs with Alliance Advisors IR. Thank you all for joining today's call to discuss OpCo Health ...

SALT LAKE CITY, July 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2025 financial results on Thursday, August 14, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts.  Management on the call will include Dwight Egan ...

Guardant Health (GH) Q2 2025 Earnings Call July 30, 2025 04:30 PM ET Company ParticipantsZarak Khurshid - VP, Investor RelationsHelmy Eltoukhy - Chairman & Co-Chief Executive OfficerAmirAli Talasaz - Co-CEO & DirectorMichael Bell - Chief Financial OfficerPuneet Souda - Senior MD - Life Science Tools & DiagnosticsTycho Peterson - MD - Global EquitiesSubbu Nambi - Managing DirectorDan Arias - Managing DirectorPatrick Donnelly - Managing DirectorYuko Oku - Equity Research AssociateSalem Salem - VP - Equity Res ...

iMDx first dd-PCR assay to combine relative and absolute measurements of dd-cfDNA into single combined scoreData show significantly improved positive predictive value (PPV) for graft rejection, which potentially broadens clinical utility for dd-cfDNA with fewer false positives, further reducing unnecessary invasive biopsies for patientsiMDx expects to evaluate combined score in ongoing FDA study (NCT07060716)iMDx will be exhibiting at Booth #324 at the World Transplant CongressNational Principal Investigato ...

SAN DIEGO, July 29, 2025 /PRNewswire/ -- QuidelOrtho earned three awards and top rankings in the 2025 IMV ServiceTrak™ Awards, presented at the Association for Diagnostics & Laboratory Medicine, recognizing excellence in customer satisfaction across key performance areas. Awards: Chemistry Best overall system performance Integrated Systems Best overall system performance Best overall service QuidelOrtho Corporation | 2025 IMV ServiceTrak Awards Karen Taylor, Senior Vice President, Customer Expe ...

LONDON, July 29, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced the appointment of Iain Miller, PhD as an Independent Director to its Board of Directors, effective 29 July 2025.Dr. Miller succeeds Yair Erez, who is stepping down from the Board to focus on other professional endeavours. The Company thanks Mr Erez for his valuable servic ...

NASHVILLE, Tenn., July 28, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will host a virtual key opinion leader (KOL) event on Friday, August 15, 2025 at 4:00 PM ET featuring Anthony Langone, MD (Associate Professor of Medicine, Division of Nephrology and Hypertension, Vanderbilt University). To register, click here. Dr. Langone, who serves as the national principal investigator (NPI) for iMDx’s ongoing kidney transplant monitoring trial, will discu ...

阿尔茨海默病药物研发进展 - 公司宣布在阿尔茨海默病国际会议(AAIC)展示其药物组合最新数据，涵盖从早期症状到临床前阶段的全面治疗方案[1] - 重点包括Phase Ib/IIa Brainshuttle™ AD研究中trontinemab的积极结果：91%受试者淀粉样蛋白斑块清除至PET阴性，ARIA-E发生率低于5%[6][7][8] - 计划2025年启动两项Phase III研究(TRONTIER 1/2)针对早期症状患者，新增Phase III试验针对临床前高风险人群[2][6] 诊断技术突破 - Elecsys® pTau217血液检测获FDA突破性设备认定，性能媲美PET扫描和脑脊液检测，可规模化应用于临床[3][9] - 真实数据显示该检测可避免75%未确诊患者的延误(平均诊断等待2.8年)，减少医疗资源消耗[4][10] - 配套启动TRAVELLER预筛查研究，通过血浆生物标志物扩大试验人群多样性[5] 药物作用机制 - Trontinemab采用Brainshuttle技术增强血脑屏障穿透性，3.6mg/kg剂量组72%患者实现深度清除(淀粉样蛋白水平<11 centiloids)[7][14][15] - 早期显著降低脑脊液和血浆中tau蛋白相关生物标志物(pTau181/217等)，安全性良好[8] - 该双特异性抗体设计针对β淀粉样蛋白聚集形态，可能延缓疾病进展[14][15] 研发战略布局 - 公司阿尔茨海默病产品线覆盖诊断工具(血液检测/CSF/数字技术)与多靶点药物，强调早期干预[16] - 通过TRONTIER研究设计体现综合策略：主要终点为18个月治疗后认知功能改善(CDR-SB量表)，次要终点包括行为症状和生活质量[5][12] - 诊断与治疗协同开发，如pTau217检测将用于临床试验患者筛选[3][9]